DOUGLAS MULINIX: Open Payments
NPI 1346284973 · DANVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,918 in 161 payments from 19 companies in 2025. Trend: 2023 $2,916 · 2024 $1,481 · 2025 $2,918
Food & beverage: $2,862Education: $56
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $435 |
| Otsuka America Pharmaceutical, Inc. | 16 | $407 |
| Vanda Pharmaceuticals Inc. | 17 | $383 |
| Axsome Therapeutics, Inc. | 13 | $349 |
| E.R. Squibb & Sons, L.L.C. | 9 | $244 |
| Collegium Pharmaceutical, Inc. | 19 | $230 |
| Corium, LLC | 11 | $165 |
| Supernus Pharmaceuticals, Inc. | 13 | $161 |
| Lundbeck LLC | 6 | $118 |
| Neurocrine BioSciences, Inc. | 4 | $91 |
Products named: CAPLYTA, HETLIOZ, Auvelity, REXULTI, COBENFY, Jornay PM, ABILIFY ASIMTUFII, Azstarys.
Industry payments across IN — which companies pay providers there.
